Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Go Capital

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 110
Average round size
info
The average size of a deal this fund participated in
$8M
Portfolio companies 80
Rounds per year 5.24
Lead investments 26
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.27
Exits 5
Key employees Soon
Stages of investment
Early Stage Venture
Private Equity
Seed

Areas of investment

  • Biotechnology
  • Health Care
  • Software
  • Medical Device
  • Medical

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Go Capital:
Typical Co-investors
Go Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Go Capital:

Funds with similar focus

Funds from France
Funds with similar focus located in France:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Digital4better

Consulting
Information Technology
Software
$1M23 Feb 2024 Nantes, Pays de la Loire, France

AVATAR MEDICAL

Education
Virtual Reality
$5M19 Feb 2024 Paris, Ile-de-France, France

Genevos

Energy
Fuel Cell
Renewable Energy
$2M18 Jan 2024 Poitou-Charentes, New Aquitaine, France

Scalinx

Semiconductor
$40M10 Jan 2024 Paris, Ile-de-France, France

Sweetch Energy

Energy
Renewable Energy
$29M18 Dec 2023 Rennes, Bretagne, France

Niryo

Education
Information Technology
Robotics
Training
$3M04 Oct 2023 Nord-Pas-de-Calais, Hauts-de-France, France

Abcely

Biotechnology
Health Care
$2M21 Sep 2023 Nantes, Pays de la Loire, France

Kanta

Software
$1M19 Sep 2023 Caen, Normandy, France

BuyCo

Logistics
Marine Transportation
SaaS
Software
Supply Chain Management
Transportation
24 Jul 2023 Marseille, Provence-Alpes-Côte d'Azur, France
News
Coave Therapeutics Closes €33M in Series B Financing

– Coave Therapeutics, a Paris, France-based clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases, raised a €21.2m ($25.1m) expansion of its Series B funding round, bringing the total raised to €33.1m ($39m).
– This round was led by Seroba Life Sciences, supported by new investors Théa Open Innovation and eureKARE alongside existing shareholders Fund+, Omnes Capital, V-Bio Ventures, Kurma Partners, Idinvest, GO Capital, and Sham Innovation Santé/Turenne.
– The company will use the proceeds to support the execution of its corporate strategy, which is focused on advancing its lead clinical program CTx-PDE6b for the treatment of PDE6b inherited retinal dystrophies, currently in Phase I/II clinical trial, towards pivotal trials, developing its AAV Ligand Conjugate (‘ALIGATER’) platform, which is designed to enhance the delivery and efficiency of AAV vectors via a proprietary chemical conjugation technology to produce targeted gene therapy products, advancing new preclinical programs, based on AAV-Ligand Conjugate capsids (coAAV), in rare CNS and Ocular diseases, including CTx-GBA1 for Parkinson’s disease and Gaucher Disease and CTx-ABCA4 for Stargardt’s disease, entering partnerships in key disease areas to progress novel coAAV candidates towards the clinic and to address other disease areas given the potential of the platform and the scope for targeting other tissues.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Go Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 110
Average round size 8M
Rounds per year 5.24
Peak activity year 2017
Lead investments 26
Follow on index 0.27
Exits 5
Group Appearance index 0.75

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Digital4better

Consulting
Information Technology
Software
$1M23 Feb 2024 Nantes, Pays de la Loire, France

AVATAR MEDICAL

Education
Virtual Reality
$5M19 Feb 2024 Paris, Ile-de-France, France

Genevos

Energy
Fuel Cell
Renewable Energy
$2M18 Jan 2024 Poitou-Charentes, New Aquitaine, France

Scalinx

Semiconductor
$40M10 Jan 2024 Paris, Ile-de-France, France

Sweetch Energy

Energy
Renewable Energy
$29M18 Dec 2023 Rennes, Bretagne, France

Niryo

Education
Information Technology
Robotics
Training
$3M04 Oct 2023 Nord-Pas-de-Calais, Hauts-de-France, France

Abcely

Biotechnology
Health Care
$2M21 Sep 2023 Nantes, Pays de la Loire, France

Kanta

Software
$1M19 Sep 2023 Caen, Normandy, France

BuyCo

Logistics
Marine Transportation
SaaS
Software
Supply Chain Management
Transportation
24 Jul 2023 Marseille, Provence-Alpes-Côte d'Azur, France
Crunchbase icon

Content report

The following text will be sent to our editors: